Literature DB >> 12791875

Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.

Hiroshi Miyake1, Yuji Iizawa, Masanori Baba.   

Abstract

CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1) is a major viral population that is transmitted by sexual intercourse and that replicates in infected individuals during the asymptomatic stage of HIV-1 infection, suggesting that agents effective against R5 HIV-1 can be expected to prevent viral transmission and delay disease progression. However, R5 HIV-1 is unable to replicate in human T-cell lines, which is an apparent obstacle to efficient and reliable susceptibility tests of compounds for their activities against R5 HIV-1. To establish a simple and rapid assay system for the monitoring of R5 HIV-1 replication and drug susceptibility, we have established a novel reporter T-cell line, MOCHA (which represents MOLT-4 cells stably expressing CCR5 and carrying the HIV-1 long terminal repeat-driven secretory alkaline phosphatase). Cells of this cell line express CD4, CXCR4, and CCR5 on their surfaces and secrete human placental alkaline phosphatase into the culture supernatants during HIV-1 infection. MOCHA cells proved to be highly permissive for the replication of R5 HIV-1 as well as CXCR4-using (X4) HIV-1, and the alkaline phosphatase activity increased in parallel with increasing HIV-1 p24 antigen levels in the culture supernatants. When HIV-1 reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors, including the CCR5 antagonist TAK-779 and the CXCR4 antagonist AMD3100, were examined for their inhibitory effects on R5 and X4 HIV-1 replication in MOCHA cells, the antiviral activities of these compounds were found to be almost identical to those previously reported in peripheral blood mononuclear cells. Thus, MOCHA cells are an extremely useful tool for detection of R5 and X4 HIV-1 replication and drug susceptibility tests.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791875      PMCID: PMC156554          DOI: 10.1128/JCM.41.6.2515-2521.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.

Authors:  C D Pilcher; J J Eron; L Ngo; A Dusek; P Sista; J Gleavy; D Brooks; T Venetta; E DiMassimo; S Hopkins
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

2.  Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.

Authors:  M Baba; H Miyake; M Okamoto; Y Iizawa; K Okonogi
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-01       Impact factor: 2.205

3.  Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

Authors:  E De Clercq; D Schols
Journal:  Antivir Chem Chemother       Date:  2001

Review 4.  HIV fusion and its inhibition.

Authors:  C C LaBranche; G Galasso; J P Moore; D P Bolognesi; M S Hirsch; S M Hammer
Journal:  Antiviral Res       Date:  2001-05       Impact factor: 5.970

5.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.

Authors:  M Baba; O Nishimura; N Kanzaki; M Okamoto; H Sawada; Y Iizawa; M Shiraishi; Y Aramaki; K Okonogi; Y Ogawa; K Meguro; M Fujino
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.

Authors:  C Spenlehauer; C A Gordon; A Trkola; J P Moore
Journal:  Virology       Date:  2001-02-15       Impact factor: 3.616

7.  Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice.

Authors:  Masaki Kawamura; Taichi Naito; Masamichi Ueno; Takami Akagi; Katsuya Hiraishi; Izumi Takai; Masahiko Makino; Takeshi Serizawa; Kazuhisa Sugimura; Mitsuru Akashi; Masanori Baba
Journal:  J Med Virol       Date:  2002-03       Impact factor: 2.327

8.  Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

Authors:  K Maeda; K Yoshimura; S Shibayama; H Habashita; H Tada; K Sagawa; T Miyakawa; M Aoki; D Fukushima; H Mitsuya
Journal:  J Biol Chem       Date:  2001-07-13       Impact factor: 5.157

9.  Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.

Authors:  K Takashima; H Miyake; R A Furuta; J I Fujisawa; Y Iizawa; N Kanzaki; M Shiraishi; K Okonogi; M Baba
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

View more
  3 in total

1.  Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.

Authors:  Tomoko Chiba-Mizutani; Hideka Miura; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Kosuke Miyauchi; Masako Nishizawa; Naoki Yamamoto; Wataru Sugiura
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

2.  High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target.

Authors:  Joan Cao; Jason Isaacson; Amy K Patick; Wade S Blair
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  TILRR Promotes Migration of Immune Cells Through Induction of Soluble Inflammatory Mediators.

Authors:  Mohammad Abul Kashem; Xiaoou Ren; Hongzhao Li; Binhua Liang; Lin Li; Francis Lin; Francis A Plummer; Ma Luo
Journal:  Front Cell Dev Biol       Date:  2020-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.